1. Home
  2. DFDV vs ALDX Comparison

DFDV vs ALDX Comparison

Compare DFDV & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFDV

DeFi Development Corp.

HOLD

Current Price

$2.93

Market Cap

93.4M

Sector

Finance

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$2.13

Market Cap

103.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFDV
ALDX
Founded
2018
2004
Country
United States
United States
Employees
16
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.4M
103.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
DFDV
ALDX
Price
$2.93
$2.13
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$45.00
$5.50
AVG Volume (30 Days)
1.1M
1.6M
Earning Date
05-13-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.58
N/A
Revenue Next Year
$23.65
N/A
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$1.07
52 Week High
$32.00
$6.18

Technical Indicators

Market Signals
Indicator
DFDV
ALDX
Relative Strength Index (RSI) 43.41 64.83
Support Level $2.61 $1.49
Resistance Level $5.22 $2.27
Average True Range (ATR) 0.29 0.15
MACD 0.03 0.03
Stochastic Oscillator 35.97 88.39

Price Performance

Historical Comparison
DFDV
ALDX

About DFDV DeFi Development Corp.

DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: